Video Experimental Relacionado
Updated: Feb 7, 2026
10:03
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
793
Interacción entre el efecto de bata blanca y la hipertensión en la rigidez arterial
Lin Jin1, Zhenyi Li1, Xinyi Li2,3
1Department of Ultrasound, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine.
Journal of hypertension
|February 6, 2026
Resumen
El efecto de bata blanca (EBC) se asocia con un aumento de la rigidez arterial y un mayor riesgo de enfermedad cardiovascular (ECV) en personas hipertensas. Este estudio encontró que el EBC predice de forma independiente una mayor rigidez arterial, especialmente en mujeres.
Área de la Ciencia:
- Cardiología
- Investigación sobre Hipertensión
- Biología Vascular
Sus antecedentes:
- El efecto de bata blanca (EBC), caracterizado por una presión arterial elevada en entornos clínicos, es un factor de riesgo debatido de enfermedad cardiovascular (ECV).
- La investigación existente sobre la asociación entre el EBC, la hipertensión y la rigidez arterial sigue siendo inconsistente, lo que requiere una mayor investigación.
Objetivo del estudio:
- Investigar la interacción entre el EBC y la hipertensión en relación con la rigidez arterial.
- Determinar si el EBC es un predictor independiente de la rigidez arterial y del riesgo de ECV.
Principales métodos:
- Se incluyó una cohorte de 7584 participantes, incluidos controles e individuos hipertensos, y se clasificaron en cuatro grupos: control, hipertensión de bata blanca (EBH), hipertensión y hipertensión no controlada de bata blanca (EBHU).
- La rigidez arterial se evaluó utilizando el índice de pulso de velocidad arterial (AVI) y el índice de volumen de presión arterial (API) mediante oscilometría de puño.
- Se emplearon análisis de regresión logística y de splines cúbicos restrictivos (RCS) para evaluar los factores de riesgo y la relación entre la API y la presión del pulso.
Principales resultados:
- Los participantes con EBHU fueron mayores y exhibieron una mayor presión del pulso (PP) y API en comparación con aquellos con EBH.
- Tanto la EBH/EBHU como la API se identificaron como determinantes independientes de la rigidez arterial y predictores significativos de alto riesgo de ECV en análisis multivariables.
- Se observó una relación significativa en forma de J entre la API y la PP tanto en individuos con EBC como sin EBC.
Conclusiones:
- Las personas que experimentan el efecto de bata blanca demuestran un aumento de la rigidez arterial periférica, con un efecto más pronunciado en las mujeres.
- El estudio confirma el EBC como un factor de riesgo independiente asociado con un mayor riesgo de ECV.
- Existe una asociación en forma de J entre los índices de rigidez arterial (API) y la presión del pulso (PP) independientemente del estado del EBC.
Palabras clave:
APIAVIIMCPAECVPADFCVRSPuntuación de Riesgo Cardiovascular de FraminghamHDL-CFCPAMPPPASCTEBCEBHEBHUíndice de volumen de presión arterialrigidez arterialíndice de pulso de velocidad arterialpresión arterialíndice de masa corporalenfermedad cardiovascularpresión arterial diastólicafrecuencia cardíacacolesterol de lipoproteínas de alta densidadpresión arterial mediapresión del pulsopresión arterial sistólicacolesterol totalefecto de bata blancahipertensión de bata blancahipertensión no controlada de bata blanca
Videos de Conceptos Relacionados
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
477
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
477
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
512
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
512
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
628
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
628
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
550
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
01:28Hypertension I: Introduction
911
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
911